Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) have earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating on the company. The average twelve-month price objective among […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) CEO Robert I. Blum sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $32.60, for a total value of $407,500.00. Following the transaction, the chief executive officer now directly owns 441,417 shares of […]
Cytokinetics (NASDAQ:CYTK – Get Rating) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday. Several other research analysts have also recently weighed in on the stock. The Goldman Sachs Group dropped their price objective on shares of Cytokinetics from $56.00 to $48.00 and set […]
StockNews.com upgraded shares of Cytokinetics (NASDAQ:CYTK – Get Rating) from a sell rating to a hold rating in a research note published on Thursday. CYTK has been the subject of a number of other reports. JMP Securities reissued a buy rating and issued a $71.00 price target on shares of Cytokinetics in a report on […]
Opaleye Management Inc. lowered its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) by 4.9% during the fourth quarter, HoldingsChannel reports. The fund owned 250,000 shares of the biopharmaceutical company’s stock after selling 13,000 shares during the quarter. Cytokinetics comprises about 4.0% of Opaleye Management Inc.’s portfolio, making the stock its 6th largest […]